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Abstract
Objective: Hypocretin deficiency causes narcolepsy and may affect neuroendocrine systems, including
TSH, ACTH and LH secretion. Symptoms can be treated effectively with sodium oxybate (SXB) in many
patients. This study was performed to compare prolactin (PRL) secretion in patients and matched
controls and establish the effect of SXB administration on PRL and sleep in both the groups.
Design: Open label intervention. Blood was sampled before and after 5 days of SXB treatment. The study
was performed at the Leiden University Medical Centre, Leiden, The Netherlands.
Methods: Subjects were admitted to the clinical research centre on both occasions.
Patients or participants: Eight male hypocretin-deficient narcolepsy with cataplexy patients and eight
controls matched for sex, age, body mass index, waist-to-hip ratio and fat percentage were enrolled.
Interventions: SXB two times 3 g per night for five consecutive nights.
Results: Patients and controls underwent 24 h blood sampling at 10 min intervals for measurement of
PRL concentrations. The PRL concentration time series was analysed with a new deconvolution
programme, approximate entropy (ApEn) and Cosinor analysis. Sleep was polygraphically recorded.
Basal and pulsatile PRL secretion, as well as pulse regularity and frequency, ApEn and diurnal
parameters were similar in patients and controls. SXB treatment caused similar nocturnal increase in
PRL secretion, advance of the acrophase and decrease in ApEn in patients and controls. Slow wave
sleep was increased to a similar extent in patients and controls.
Conclusion: This detailed study did not demonstrate altered PRL secretion in hypocretin-deficient
narcolepsy patients during the basal state or during SXB administration. Therefore, hypocretin
signalling is unlikely to be a regulator of the lactotrophic system.
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Introduction
Narcolepsy is a debilitating disorder characterised by
excessive daytime sleepiness (EDS), cataplexy, hypnago-
gic hallucinations, sleep paralysis and nocturnal sleep
disturbances (1). In recent years, obesity and hormonal
alterations have been recognised as additional features
of the narcoleptic syndrome (2).
Interest in energy homeostasis in narcolepsy increased
after the discovery of hypocretin deficiency as the cause
of this disorder since hypocretins (orexins) are known to
influence feeding behaviour, wakefulness and energy
expenditure (3–6). Hypocretins are also involved in the
control of the secretion of various hormones (7–11).
Prolactin (PRL) is a polypeptide hormone, which is
primarily produced in the anterior pituitary gland (12).
Apart from its role in lactation and reproduction, PRL
also takes part in the regulation of body energy
homeostasis (12, 13). Prolonged hyperprolactinaemia
is often accompanied by weight gain in humans, which
can be ameliorated by normalisation of serum PRL (13).
The major physiological regulator of PRL release is
dopamine from tubero-infundibular origin. Hypo-
thalamic dopamine inhibits the basally high secretory
tone of pituitary lactotrophs by binding to D2 receptors
expressed in their cell membranes (14, 15). Hence,
alterations in the dopaminergic system, as described
previously in the post-mortem brains of narcoleptic
humans, may cause changes in PRL secretion (16).
However, earlier reports on PRL secretion in narcolepsy
patients have been inconclusive, showing either
increased, decreased or normal levels (2, 17–19).
These discrepancies are likely due to the use of only
few baseline measurements of hormone levels, small
sample size, relatively poor matching or too long blood
sampling intervals, which are not adequate to assess
either the pulsatile nature of PRL secretion or its total
daily production rate.
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Sodium oxybate (SXB) or gamma-hydroxybutyrate
(GHB) is effective in the treatment of narcolepsy. It
reduces cataplexy, improves nocturnal sleep quality and
higher doses of SXB may also reduce EDS (20).
Although the exact mode of action is still unclear, SXB
acts on gamma-aminobutyric acid type B (GABAB)
and has an impact on dopamine and serotonin release
(21, 22). Therefore, SXB treatment may be expected to
alter PRL secretion. Indeed, there are reports that SXB
administration may increase PRL secretion (23, 24).
Several reports have been published on PRL and sleep;
however, the precise association between PRL release
and sleep still remains to be elucidated (23–28).
We hypothesised that changes in hypothalamic
hypocretin signalling in narcoleptic patients may give
rise to altered PRL secretion. In addition, we aimed
to determine the effect of SXB administration on PRL
secretion and sleep, both in a healthy and in a
hypocretin-deficient state. Therefore, using a com-
bination of polysomnography and state-of-the-art
endocrine techniques, we compared PRL secretion
between hypocretin-deficient narcoleptic subjects and
matched controls both at baseline and after five nights
of SXB administration.
Subjects and methods
Subjects
Eight male narcolepsy patients with definite cataplexy
were included, who fulfilled the diagnostic criteria of
the 2nd edition of the International Classification for
Sleep Disorders (29). All narcolepsy patients were
hypocretin-1 deficient and free of medication for at
least 2 weeks before the study. Only one of the patients
received prolonged SXB administration in advance. He
did stop taking SXB 20 days prior to the study. One
patient took SXB in the past for a short period of time and
took stimulants on demand. Another patient was tapered
off antidepressants. Five patients were not taking any
drugs at the time of enrolment. All consecutive male
patients eligible for the study were asked to participate.
Eight healthy controls, matched for sex, age, body mass
index (BMI), waist-to-hip ratio (WHR) and fat percentage,
were included for comparison. Bioelectrical impedance
analysis (Bodystat, Douglas, Isle of Man, UK) was used
to estimate fat percentage. Subjects were eligible for study
after exclusion of hypertension, any known history of
pituitary, psychiatric or neurological disease (other than
narcolepsy), alcohol or drug abuse, recent weight change
(O3 kg weight change within the last 3 months), a sleep
disorder history assessed through clinical interview
(controls) and endurance sports. Routine laboratory
tests were performed to rule out diabetes (fasting plasma
glucose O6.9 mmol/l), anaemia, as well as hepatic and
renal failure. The study was performed at Leiden
University Medical Centre, Leiden, The Netherlands.
The study was approved by the ethics committee of the
Leiden University Medical Centre. Written informed
consent was obtained from all subjects.
Protocol
Subjects were admitted to the Clinical Research Centre
for 24 h blood sampling. A cannula was inserted into
the antecubital vein 45 min before the start of blood
sampling at 1200 h. Blood samples were collected with
S-monovetten (Sarstedt, Etten-Leur, The Netherlands)
from a three-way stopcock attached to a 0.9% NaCl and
heparin (1 U/ml) infusion (750 ml/24 h) to keep the
cannula from clotting. Sampling was performed
through a long line to prevent sleep disruption by
investigative manipulations. For PRL measurements,
blood was collected in serum tubes at 10 min intervals.
After clotting, the blood was centrifuged within 30 min
of sampling (1250 g at 4 8C for 20 min). Subsequently,
plasma was divided into separate aliquots in Sarstedt
tubes and stored at K80 8C until assay. Three
standardised meals were served at 0830, 1300 and
1800 h (Nutridrink, Nutricia, Zoetermeer, The Nether-
lands; 1.5 kcal/ml, 2100 kcal/day; macronutrient
composition per 100 ml: protein, 6 g; fat, 5.8 g;
carbohydrate, 18.4 g). Subjects remained (semi)supine
except for bathroom visits. Daytime naps were allowed.
Lights were switched off at 2300 h and turned on at
0730 h the next day. Twenty-four hour sampling was
performed at baseline and on the 5th day of SXB
administration in two night-time doses of 3 g at 2300
and 0300 h. This starting dose, higher than the usual
of 2.25 g, permitted to elicit some effect in a few days of
administration. To monitor side effects, the first night of
administration was done clinically.
Sleep analysis
Sleep was polygraphically recorded throughout both
sampling occasions, using an Embletta X100 recorder
(Embla, Broomfield, CO, USA). The recordings were
scored visually by an experienced sleep technician
at 30 s intervals according to the AASM criteria (30).
To allow assessment of the association between changes
in serum PRL levels (measured every 10 min) and sleep
stages (scored every 30 s), sleep profiles were divided
into 10 min segments, separating consecutive PRL
measurements as described previously (31). These
segments were condensed from the 30 s scoring
intervals by calculating the percentage of time spent
in stages I and II non-rapid eye movement (REM) sleep,
slow wave sleep (SWS) and REM sleep.
Assays
Serum PRL concentrations were measured with a
sensitive time-resolved immunofluorometric assay
with a detection limit of 0.04 mg/l (Delfia, Wallac Oy,
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Turku, Finland). The assay was calibrated against the
3rd WHO standard 84/500, 1 ng/mlZ36 mU/l. The
intra-assay coefficient of variation varied from 3.0 to
5.2%, while the inter-assay coefficient of variation was
between 3.4 and 6.2% (in the 0.1–250 mg/l concen-
tration range). In order to minimise inter-assay
variability, samples from each patient and matched
control were analysed in the same run.
Calculations and statistics
Deconvolution analysis
PRL concentration time series were analysed using a
recently developed automated deconvolution method,
which was mathematically verified by direct statistical
proof and empirically validated using hypothalamo-
pituitary sampling and simulated pulsatile time series
(32). For PRL, the fast half-life was represented as
3.5 min constituting 37% of the decay amplitude and
the slow half-life was represented as an unknown
variable between 20 and 50 min (33, 34). All candidate
pulse-time sets were deconvolved. Statistical model
selection was then performed to distinguish among
the independently framed fits of the multiple candidate
pulse-time sets using the Akaike information criterion
(35). The parameters (and units) are frequency
(number of bursts per total sampling period, l of the
Weibull distribution), regularity of inter-pulse intervals
(unitless g of Weibull), slow half-life (min), basal and
pulsatile secretion rates (concentration units/session),
mass secreted per burst (concentration units) and wave
form shape (mode or time delay to maximal secretion
after objectively estimated burst onset, min).
Approximate entropy
Approximate entropy (ApEn) (1, 20%), was used as a
scale- and model-independent regularity statistic to
quantify the orderliness (regularity) of PRL release.
Higher ApEn denotes greater disorderliness (irregu-
larity) of the secretion process. Mathematical models
and clinical experiments have established that greater
irregularity signifies decreased feedback control with
high sensitivity and specificity (bothO90%) (36).
Diurnal variation
The wave form of individual PRL profiles was quantified
by a best-fit curve obtained using a locally weighted
regression procedure with a regression window of 4 h
and a Gaussian kernel (37). The values (and timings) of
the acrophase and the nadir were defined as the levels
(the timings) corresponding to the maximum and the
minimum of the best-fit curve respectively. The
amplitude was defined as 50% of the difference between
the acrophase and the nadir values.
Statistical analysis
Data are presented as meanGS.E.M., unless otherwise
specified. Statistical comparisons were made with either
Student’s t-test or repeated measures ANOVA when
appropriate. Pearson’s correlation coefficient was applied
to assess all correlations. Cross-correlation analysis was
applied to assess the association between PRL levels and
the percentage of time spent in various sleep stages in the
preceding 10 min sampling interval, taking into account
all of the sampling intervals during sleep (38). Statistical
calculations were performed using Systat software
(version 11, Systat Software, Inc., San Jose, CA, USA)
and SPSS (release 17.0, SPSS, Inc., Chicago, IL, USA). All
tests were two-tailed and significance level was set at 0.05.
Results
Narcoleptic patients and controls did not differ with
respect to gender (male), age (38.0G4.7 vs 37.9G4.1,
PZ0.984 respectively), BMI (28.1G1.6 vs 27.4G1.4,
18
16
14
12
10
8
6
4
2
12 15 18 21 24
Time
Basal
Treatment
Oxybate
Pr
ol
ac
tin
 (µ
g/
l)
Pr
ol
ac
tin
 (µ
g/
l)
Control subjects
3 6 9 12
18
16
14
12
10
8
6
4
0
2
12 15 18 21 24
Time
Basal
Treatment
Oxybate
Patients
3 6 9 12
Figure 1Mean24 hplasmaprolactinconcentrationGS.E.M., beforeand
after the SXB administration in narcolepsy patients (nZ8) and controls
(nZ8). The downward arrows indicate ingestion of SXB in treatment
condition. The dark horizontal bar indicates the lights off period.
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PZ0.742), fat percentage (23.6G2.1 vs 23.4G1.7,
PZ0.946) and WHR (0.92G0.03 vs 0.90G0.02,
PZ0.579). As expected, in narcolepsy patients the
mean BMI was in the overweight range. Ingestion of
SXB was well tolerated and apart from mild drowsiness
no other side effects were reported.
The mean 24 h PRL concentration in narcolepsy
patients was 5.13G0.47 mg/l at baseline and 5.65
G0.52 mg/l during the SXB administration (P!0.001,
see Fig. 1). In controls, it was 6.78G1.68 and 7.40
G1.66 mg/l respectively (P!0.001). The PRL concen-
tration strongly increased shortly after the adminis-
tration of each dose of SXB. In patients, an increase from
4.56G0.26 to 12.08G1.61 mg/l occurred (P!0.001),
and in controls PRL increased from 6.28G1.72 to
14.07G2.85 mg/l (P!0.001) during the first SXB
administration. After the second dose, serum PRL
increased from 5.12G0.36 to 12.26G2.74 mg/l in
patients (P!0.001) and from 7.28G1.94 to 13.82
G1.86 mg/l in controls. The effect of SXB was not
statistically different between patients and controls.
Deconvolution analysis
At baseline, there were no significant differences in
basal, total or pulsatile PRL secretion between narco-
lepsy patients and controls (Table 1). However, there
was a clearly stimulatory effect of SXB on PRL secretion.
Basal secretion increased slightly after SXB adminis-
tration, whereas total PRL secretion increased with
20% in patients and nearly 25% in controls, most likely
resulting from an increase of more than 60% in mean
pulse mass in both the groups (Table 1).
Diurnal variation
The acrophase of serum PRL concentrations shifted
after SXB administration to 1.5 h earlier in controls and
3 h earlier in narcolepsy patients (Table 2). Similarly,
the nadir advanced in both the groups after the SXB
administration. The amplitude increased significantly in
both the groups indicating a greater degree of diurnal
variation in PRL secretion after SXB treatment. Inter-
group differences as well as group!treatment
interaction effects were not significant, indicating a
similar effect of SXB on both narcolepsy and control
subjects.
Approximate entropy
The ApEn values decreased in both the groups after the
SXB administration, reflecting greater regularity of PRL
release. There were no differences in baseline ApEn
values nor was the group!treatment interaction effect
significant (Fig. 2).
Table 1 Deconvolution of serum prolactin concentration profiles in narcolepsy patients and healthy controls. Data are shown as meanGS.E.M.
Each group consisted of eight subjects. Comparisons were made using Student’s t-test (column 8) and two-way ANOVA for repeated
measurements. Secretion data are expressed in mass units per litre hormone distribution volume.
Narcolepsy Controls
Narcolepsy versus
controls
Baseline SXB Baseline SXB Baseline SXB Treatment Interaction
Pulse frequency (no/24 h) 23.5G0.9 16.6G1.6 21.3G0.8 18.1G1.8 0.08 0.74 0.006* 0.24
Half-life (min) 39G4.7 33G2.5 39G4.1 33G2.5 0.93 0.83 0.16 0.96
Basal secretion (mg/l per 24 h) 91G16.8 115G18 144G59 163G62 0.40 0.43 0.04* 0.83
Pulsatile secretion (mg/l per 24 h) 93G8.0 105G17.2 105G15.0 147G28 0.48 0.26 0.06 0.29
Total secretion (mg/l per 24 h) 184G20.0 220G32.0 249G73 310G85 0.40 0.31 0.000* 0.83
Mean pulse mass (mg/l) 3.99G0.37 6.69G1.15 4.89G0.55 7.87G1.07 0.20 0.69 0.005* 0.25
Mode (min) 19G2.0 20.6G1.8 18.2G1.7 18.1G3.1 0.77 0.41 0.75 0.71
l (events/24 h) 21.4G0.7 15.1G1.5 19.3G0.7 16.3G1.7 0.06 0.69 0.005* 0.25
g (dimensionless) 2.19G0.17 2.05G0.11 2.18G0.12 2.30G0.20 0.93 0.54 0.97 0.31
*P!0.05.
Table 2 Diurnal variation in prolactin concentrations. Data are shown as mean clock timeGS.E.M. in minutes. Statistical
comparisons were performed with ANOVA for repeated measurements. Between subjects and interaction P values were
all non-significant.
Baseline SXB
Treatment effect
Controls Patients Controls Patients (P)
Acrophase 5:05G51 5:45G84 3:37G43 2:34G44 0.01*
Nadir 15:53G48 14:06G38 13:19G47 13:33G42 0.02*
Amplitude (mg/l) 2.19G0.17 2.08G0.30 3.35G0.47 2.71G0.49 0.015*
*P!0.05.
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Sleep recordings
On average, compared with controls, narcolepsy
patients spent significantly less time awake both during
basal conditions and SXB treatment (Table 3). During
the day (defined as the lights on period between 0730
and 2300 h), narcolepsy patients spent significantly less
time awake, while significantly more time was spent in
non-REM sleep, regardless of treatment (Table 3). The
SXB administration resulted in a significant decrease in
stages I and II non-REM and REM sleep over 24 h in
both the groups (PZ0.011 and 0.009 respectively),
while it significantly increased the time spent in SWS
(PZ0.001). During the day, SXB treatment reduced the
time spent in stages I and II non-REM and REM sleep
(PZ0.038 and 0.041 respectively), while it tended to
increase wakefulness (PZ0.098). The percentage of
SWS during the night more than doubled in both the
groups in response to SXB treatment (narcolepsy: 6.5
G1.9 vs 16.5G3.0%; controls: 7.1G1.9 vs 18.5
G2.4%; PZ0.001 for treatment effect), whereas there
were trends for decreases in the percentages of stages I
and II non-REM and REM sleep. The cross-correlation
between SWS and PRL release strongly increased
after SXB treatment in both narcolepsy patients
(K0.03G0.03 vs 0.47G0.12) and controls (0.09
G0.06 vs 0.50G0.07), P%0.001 for treatment effect
(Fig. 3). However, the SXB administration did not
significantly affect the cross-correlation between PRL
release and REM sleep in either narcolepsy patients
(0.12G0.05 vs 0.04G0.03) or controls (0.22G0.04 vs
0.10G0.07), PZ0.070 for treatment effect. Similarly,
the cross-correlation between PRL secretion and the
percentage of time spent in stages I and II non-REM
sleep did not change after SXB treatment (0.10G0.09 vs
0.19G0.07 in narcolepsy patients and 0.47G0.06 vs
0.37G0.10 in controls, PZ0.957 for treatment effect).
Discussion
This is the first study in which advanced endocrinolo-
gical modelling has been applied to accurately assess the
secretory dynamics of PRL secretion and its response to
SXB challenge in narcolepsy patients. As PRL secretion
dynamics was similar in hypocretin-deficient narcolepsy
patients and healthy controls, our findings indicate that
hypocretin is unlikely to be a major physiological
regulator of PRL secretion. We showed that the SXB
administration markedly increased PRL secretion and
that it enhanced the association between PRL release
and SWS. As SXB is known to modulate dopamine
release, the major regulator of PRL secretion, these
findings suggest that changes in the tubero-infundibular
dopaminergic output could underlie the effect of SXB on
PRL release. These effects of SXB are unlikely to involve
the hypocretin system, since SXB treatment-stimulated
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Figure 2 Approximate entropy of serum prolactin concentration
series in patients (lower) and controls (upper) before (left column)
and during the SXB (right column) administration. The horizontal
black bar indicates the mean.
Table 3 Sleep patterns before and after sodium oxybate administration. Data are shown as meanGS.E.M. The data
are presented as percentages of sleep stages during the 24 h of study, before and after the SXB administration.
Unpaired t-tests were used to assess the differences between the two groups.
Baseline Sodium oxybate
Patients Controls P Patients Controls P
Wake total (%) 60.8G2.9 68.7G2.0 0.044* 60.8G2.2 70.1G2.4 0.013*
Wake day (%) 79.4G4.2 95.6G2.1 0.004* 82.9G3.2 97.3G1.0 0.001*
Wake night (%) 25.8G5.7 18.4G4.0 0.310 19.2G4.3 19.2G5.8 0.999
Stages I/II total (%) 29.1G1.4 25.0G2.4 0.155 26.3G1.4 21.1G2.2 0.063
Stages I/II day (%) 14.6G3.0 2.5G1.6 0.003* 11.1G2.5 1.6G1.0 0.005*
Stages I/II night (%) 55.1G2.5 65.6G5.7 0.114 53.5G3.7 56.4G5.3 0.647
SWS total (%) 3.7G0.7 2.5G0.7 0.239 7.6G1.2 6.6G0.9 0.534
SWS day (%) 2.1G0.6 0.03G0.03 0.005* 2.7G1.1 0.05G0.05 0.041*
SWS night (%) 6.5G1.9 7.1G1.9 0.843 16.5G3.0 18.5G2.4 0.611
REM total (%) 6.3G1.8 3.7G0.8 0.191 4.7G1.0 2.1G0.8 0.070
REM day (%) 2.9G1.4 0.8G0.5 0.203 1.2G0.5 0.0G0.0 0.032*
REM night (%) 12.6G3.0 8.8G1.8 0.305 10.8G2.1 5.8G2.3 0.127
*P!0.05.
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PRL release did not significantly differ between narcolepsy
patients and controls.
PRL secretion is under inhibitory control of dopamine
released from the tubero-infundibular dopaminergic
neurons (TIDA) (12). Other inhibitors of PRL release
include somatostatin and neuropeptide Y (NPY), while
TRH, serotonin, oestrogen, oxytocin, as well as stress
and light stimulate PRL secretion (12). GABA has a dual
effect on PRL secretion: by inhibiting TIDA neurons it
stimulates PRL secretion whereas it inhibits PRL release
via a non-dopaminergic pathway (12). The effect of
hypocretins on PRL release is still subject to debate.
A study in male rats showed that i.c.v. administration of
hypocretin-1 (orexin A) reduces plasma PRL through a
pathway that appears to be partly independent of the
dopaminergic system (11). Fasting upregulates hypo-
cretin-1 and NPY, which in turn stimulates TIDA
neuronal activity and inhibits PRL secretion (39). This
effect of hypocretin-1 on dopamine, however, seems to be
indirect and mediated through NPY (40). As we found
no indications for altered PRL secretion in a hypocretin-
deficient state, our findings do not support a role of
hypocretin in the regulation of PRL secretion. Con-
versely, our data also do not provide evidence for the
possibility that disrupted PRL release contributes to sleep
disturbance in narcolepsy.
In contrast to earlier reports in the late seventies we
did not find any evidence for decreased PRL secretion in
narcolepsy patients (18, 19). This discrepancy is likely
due to the application of suboptimal analytical tech-
niques in previous studies. Moreover, it is important to
note in this context, that, for obvious reasons,
hypocretin deficiency was not established in patients
included in these early studies. A more recent study
reported elevated levels of PRL in 13 narcolepsy patients
(7 with typical cataplexy) compared with controls.
However, in this study, which included predominantly
women, the groups were not matched for BMI, and PRL
levels were measured only on a single time point (17).
As PRL secretion exhibits a marked circadian variation,
is more variable in women, and is positively associated
with body weight, differences in these factors may have
been responsible for the differences in PRL levels
between narcoleptics and controls in this study (12).
SXB administration resulted in a marked increase in
PRL secretion in both narcoleptics and controls. This
finding is well in line with previous reports. A nearly
threefold increase in PRL within 15 min of a 2.5 g GHB
injection and a fivefold increase after 1 h were reported
in healthy young men (23). Likewise, van Cauter
et al. (24) reported a dose-dependent increase in PRL
secretion after the SXB administration in healthy
humans. The mechanism through which SXB stimu-
lates PRL secretion is still unclear. SXB can influence
dopaminergic, serotonergic and GABAB signalling, and
activation of these systems could initiate PRL release
(21, 22). Systemic administration with low amounts of
SXB generally induces hyperpolarisation of dopamin-
ergic structures with a reduction in dopamine release,
thereby enhancing PRL secretion (22). In addition, SXB
increases the turnover of serotonin, a PRL-releasing
factor, most likely due to an increase in available
tryptophan, a precursor of serotonin (15, 22). Addition-
ally, GABAB receptor stimulation may also have a
stimulatory effect on serotonin and PRL release (22).
Moreover, GHRH increases GH and PRL secretion (41).
It is conceivable that SXB stimulates GHRH release and
thereby promotes both GH and PRL. However, since
dopamine is the major regulator of PRL secretion, the
potentiating effect of SXB on PRL release is most likely
due to its action on the hypothalamic TIDA neurons.
In accordance with a previous study, we did not find
an association between PRL release and SWS during the
basal state (25). However, after SXB administration the
cross-correlation between PRL levels and SWS sub-
stantially increased. As the effect of SXB administration
on PRL release is likely due to its inhibition of the
activity of TIDA neurons, this finding suggests that the
suppression of the hypothalamic dopaminergic system
may also be responsible for the enhancing effect of SXB
on SWS. Alternatively, a mechanism upstream of the
TIDA system with effects on both sleep regulation and
hypothalamic dopaminergic activity may be involved.
In any case, this mechanism is unlikely to include the
hypocretinergic system since the facilitating effect of
SXB on the cross-correlation between PRL and SWS was
similar in narcoleptics and controls. Further studies are
needed to elucidate the exact nature of this novel
regulatory circuit.
A potential limitation of this study is the relatively
small number of participants. However, this limitation is
partly offset by the application of accurate assessment of
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Figure 3Cross-correlation coefficientsbetweenPRL levelsandSWS.
Sodium oxybate treatment resulted in a substantial increase in the
coupling between PRL release and SWS as evidenced by a significant
increase in the cross-correlation (P!0.001 for treatment effect).
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hormone secretory dynamics, which would have been
unfeasible in a larger group of subjects due to both the
expensive and laborious nature of the experiments.
Additionally, our subjects were very closely matched.
In conclusion, we found no evidence for altered PRL
secretion in hypocretin-deficient narcolepsy patients
either during the basal state or after the SXB
administration. Therefore, hypocretin signalling is
unlikely to be a major regulator of the lactotrophic
system. Moreover, our findings suggest that the marked
stimulatory effect of SXB on PRL release and SWS is
mediated through its influence on the hypothalamic
dopaminergic system.
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